While melanoma is recognized to exhibit high heterogeneity, a BRAF V600E mutation present in a gene encoding a member of the Ras/MAPK (mitogen-activated protein kinase) signaling pathway is a predominant genetic aberration detected in over 40% of melanoma patients [3,4]. This evidence concerns the gene WNK2 and melanoma.